GENE ONLINE|News &
Opinion
Blog

2021-08-03| Asia-Pacific

Astellas Makes a $440M+ Pact with Minovia to Develop Mitochondrial Cell Therapies

by Tyler Chen
Share To

Mitochondrial dysfunction is a genetic condition where the mitochondria fail to produce enough energy for the cell and could lead to diseases such as Alzheimer’s disease, muscular dystrophy, cancer, or diabetes. The tricky thing is that the condition could affect most body parts, including the brain, nerves, heart, eyes, or pancreas. Unfortunately, it currently has no cure.

 

A $440+ Million Deal to Challenge the Status Quo

On July 30th, Japan’s Astellas Pharma and Israel-based biotech Minovia Therapeutics announced a $440 million plus deal, aiming to develop and commercialize allogeneic cell therapies for mitochondrial diseases.

As per the terms, Astellas will provide its genetically engineered, induced pluripotent stem cells (iPSCs), a type of cell that can turn into all adult cells, while Minovia will use its mitochondrial augmentation therapy (MAT) platform to develop treatments that infuse healthy mitochondria to the mitochondrial dysfunctional cells and cure the disease.

 

Accelerating Off-the-Shelf Cell Therapy Development

Under the agreement, Minovia will receive $20 million upfront and $420 million per product in future development, regulatory and commercial milestone payments from Astellas.

“We believe this partnership is critical to accelerating the development of off-the-shelf, allogeneic cell therapy programs for the many patients living with mitochondrial diseases caused by mitochondrial dysfunction,” said Minovia’s co-founder and CEO, Natalie Yivgi-Ohana, Ph.D.

It should be noted that the platform is still under clinical trials and is used on patients with Pearson syndrome, one of the mitochondrial diseases, with autologous CD34+ hematopoietic stem cells. The Phase I/II trial began dosing in June 2019 and is the first mitochondrial cell therapy trial to treat mitochondrial disease.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Looking Back at the Cell and Gene Therapy Leaders That Made Waves in 2024
2025-03-31
Character Biosciences Secures $93M for Clinical Trials Targeting Dry AMD
2025-03-26
How Minaris is Tackling the Scalability Challenge in Cell and Gene Therapy: A Conversation with CEO, Dr. Hiroto Bando
2024-11-26
LATEST
Eli Lilly’s Orforglipron Shows Phase 3 Success: First Oral GLP-1 Drug for Type 2 Diabetes and Weight Loss
2025-04-21
Dupixent Makes History with FDA Approval as First New CSU Treatment in Over a Decade
2025-04-20
Multiple PCV Doses May Be Needed for Immunocompromised Type 2 Diabetics to Maintain Protection, Study Finds
2025-04-19
Multiple PCV Doses May Be Needed for Immunocompromised Individuals with Type 2 Diabetes
2025-04-19
Dr. Lauren Krupp, FAAN, Advocates Early Intervention and Family Support in Pediatric MS Treatment.
2025-04-19
Dr. Lauren B. Krupp Recommends Early, Aggressive Treatment with High-Efficacy Therapies for Pediatric Multiple Sclerosis
2025-04-19
GSK’s Blenrep Scores World-First Approval in UK for Multiple Myeloma
2025-04-17
EVENT
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-04-26
SABPA OC/LA 17th Annual Biomedical Forum
Irvine, California, United States
2025-05-03
29th Taiwan Joint Cancer Conference 2025
Taipei, Taiwan
2025-05-05
Swiss Biotech Day 2025
Basel, Switzerland
Scroll to Top